Swissmedic publishes its Annual Report and financial statements for 2024
Bern, 06.06.2025 — On 6 June 2025 the Federal Council approved the reporting of Swissmedic, the Swiss Agency for Therapeutic Products, for the previous year, thereby discharging the Swissmedic Agency Council of its responsibilities for 2024. The key performance indicators showed a positive trend. The Swiss Agency for Therapeutic Products promoted access to innovative treatments through fast-track procedures, international cooperation and its Innovation Office, which has now been definitively established, so that patients in Switzerland are able to benefit sooner from promising treatments. Swissmedic has specifically invested in the upgrading of its IT infrastructure: in 2024, the Swissmedic Public Cloud and the online databases SwissGMDP and swissdamed were launched. The Agency posted a deficit of around 23 million Swiss francs for the 2024 financial year. This is partly due to the digital transformation process and is covered by the reserves created in recent years.